1
|
Karami C, Mollaei H, Arabzadeh SA, Mazloum jalali K, Amerkani S, Pashangzadeh S, Nikpour N. The mutations frequency of enhancer II/HBx regions of hepatitis B virus in acutely infected Iranian patients: a cross-sectional study. IRANIAN JOURNAL OF MICROBIOLOGY 2022; 14:554-562. [PMID: 36721514 PMCID: PMC9867647 DOI: 10.18502/ijm.v14i4.10242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Background and Objectives The viral transactivator HBx protein affect cellular, viral and pregenomic factors pathway. Mutations in this protein can produce new viruses with new antigenic determinants that are generally related to developing cancerous. Materials and Methods In this cross-sectional study, 33 serum samples of patients diagnosed with acute HBV infection were investigated for HBeAg and HBV DNA viral load and HBx gene mutations. mutation in the HBx protein detected by sequencing analysis. Results Out of the 33 samples, 19 samples were males (57.6%), and 14 samples were females. 15 (45.5%) were positive for HBx DNA and 18 patients were negative for HBx DNA (54.5%). After sequencing, three mutations were recognized in HBx at nucleotide positions 147, 148, and 391 that were stationed to G1524A, G1525A, and G1767C mutations. Conclusion The analysis result of this study shows G1524A and G1525A mutations that an important role in altering the inhibition function of the HBx activity domain. The G1767C mutation inactivates HBx transactivation activity. These mutations have a critical role in the pathogenicity of the virus, and the intensity of hepatic tissue demolition and the development of cirrhosis or carcinoma in patients can be understood.
Collapse
Affiliation(s)
- Chiman Karami
- Department of Microbiology, Parasitology and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Hamidreza Mollaei
- Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
| | - Seyed Alimohammad Arabzadeh
- Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
| | - Kamyar Mazloum jalali
- Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran,Reference Laboratory, Qazvin University of Medical Sciences, Qazvin, Iran,Corresponding author: Kamyar Mazloum Jalali, MSc, Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran; Reference Laboratory, Qazvin University of Medical Sciences, Qazvin, Iran. Tel: +98-911-1480355 Fax: +98-3433257665
| | - Saman Amerkani
- Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
| | - Salar Pashangzadeh
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
| | - Najmeh Nikpour
- Department of Microbiology and Medical Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
2
|
Panasiuk YV, Vlasenko NV, Churilova NS, Klushkina VV, Dubodelov DV, Kudryavtseva EN, Korabelnikova MI, Rodionova ZS, Semenenko TA, Kuzin SN, Akimkin VG. [Modern views on the role of X gene of the hepatitis B virus (Hepadnaviridae: Orthohepadnavirus: Hepatitis B virus) in the pathogenesis of the infection it causes]. Vopr Virusol 2022; 67:7-17. [PMID: 35293184 DOI: 10.36233/0507-4088-84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 03/15/2022] [Indexed: 11/05/2022]
Abstract
The review presents information on the role of hepatitis B virus (Hepadnaviridae: Orthohepadnavirus: Hepatitis B virus) (HBV) X gene and the protein it encodes (X protein) in the pathogenesis of viral hepatitis B. The evolution of HBV from primordial to the modern version of hepadnaviruses (Hepadnaviridae), is outlined as a process that began about 407 million years ago and continues to the present. The results of scientific works of foreign researchers on the variety of the influence of X protein on the infectious process and its role in the mechanisms of carcinogenesis are summarized. The differences in the effect of the X protein on the course of the disease in patients of different ethnic groups with regard to HBV genotypes are described. The significance of determining the genetic variability of X gene as a fundamental characteristic of the virus that has significance for the assessment of risks of hepatocellular carcinoma (HCC) spread among the population of the Russian Federation is discussed.
Collapse
Affiliation(s)
- Y V Panasiuk
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - N V Vlasenko
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - N S Churilova
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - V V Klushkina
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - D V Dubodelov
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - E N Kudryavtseva
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - M I Korabelnikova
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - Z S Rodionova
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - T A Semenenko
- FSBI «National Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya» of the Ministry of Health of Russia
| | - S N Kuzin
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| | - V G Akimkin
- FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
| |
Collapse
|
3
|
Wungu CDK, Amin M, Ruslan SEN, Purwono PB, Kholili U, Maimunah U, Setiawan PB, Lusida MI, Soetjipto S, Handajani R. Association between host TNF-α, TGF-β1, p53 polymorphisms, HBV X gene mutation, HBV viral load and the progression of HBV-associated chronic liver disease in Indonesian patients. Biomed Rep 2019; 11:145-153. [PMID: 31565220 PMCID: PMC6759598 DOI: 10.3892/br.2019.1239] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 08/12/2019] [Indexed: 02/07/2023] Open
Abstract
In developing countries, including Indonesia, there is a high mortality rate associated with the progression of hepatitis B virus (HBV)-associated chronic liver disease (CLD). The pathogenesis of HBV infection is influenced by viral and host factors. To determine potential associations between these factors, host single nucleotide polymorphisms (SNPs) on TNF-α, TGF-β1 and p53, HBV X gene mutation and HBV viral load were investigated in patients with HBV-associated CLD in Surabaya, Indonesia. Sera were collected from 87 CLD patients with HBV infection. TNF-α, TGF-β1 and p53 SNPs were genotyped by PCR restriction fragment length polymorphism. The HBV X gene was sequenced and compared with reference strains to determine mutations and the viral load was measured using reverse transcription-quantitative PCR. In Indonesian patients, no association between TNF-α, TGF-β1 and p53 SNPs and CLD or X gene mutation were identified. A total of 23% (20/87) of samples had HBV X gene mutations, including ten substitution types, one deletion and one insertion. Multinomial regression analysis revealed that the K130M/V131I mutations were correlated with CLD progression (OR, 7.629; 95% CI, 1.578-36.884). Significant differences in viral load were found in HBV-infected patients who had X gene mutations, such as R87W/G, I127L/T/N/S and K130M/V131I mutations (P<0.05). The presence of K130M and V131I mutations may be predictive for the progression of HBV-associated CLD in Indonesia.
Collapse
Affiliation(s)
- Citrawati Dyah Kencono Wungu
- Department of Medical Biochemistry, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia.,Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia
| | - Mochamad Amin
- Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia
| | - S Eriaty N Ruslan
- Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia
| | - Priyo Budi Purwono
- Department of Medical Microbiology, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia
| | - Ulfa Kholili
- Department of Internal Medicine, Faculty of Medicine, University of Airlangga, Dr Soetomo General Hospital, Surabaya 60286, Indonesia
| | - Ummi Maimunah
- Department of Internal Medicine, Faculty of Medicine, University of Airlangga, Dr Soetomo General Hospital, Surabaya 60286, Indonesia
| | - Poernomo Boedi Setiawan
- Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia.,Department of Medical Microbiology, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia
| | - Maria Inge Lusida
- Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia.,Department of Medical Microbiology, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia
| | - Soetjipto Soetjipto
- Department of Medical Biochemistry, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia.,Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia
| | - Retno Handajani
- Department of Medical Biochemistry, Faculty of Medicine, University of Airlangga, Surabaya 60131, Indonesia.,Institute of Tropical Disease, University of Airlangga Campus C, Mulyorejo, Surabaya 60286, Indonesia
| |
Collapse
|
4
|
Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect 2018; 25:906.e1-906.e7. [PMID: 30472417 DOI: 10.1016/j.cmi.2018.11.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 11/06/2018] [Accepted: 11/09/2018] [Indexed: 02/07/2023]
Abstract
OBJECTIVE We aimed to investigate HBx genetic elements correlated with hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) and their impact on (a) HBV replicative efficiency, (b) HBx binding to circular covalently closed DNA (cccDNA), (c) apoptosis and cell-cycle progression, and (d) HBx structural stability. METHODS This study included 123 individuals chronically infected with HBV: 27 with HCC (77.9% (21/27) genotype D; 22.1% (6/27) genotype A) and 96 without HCC (75% (72/96) genotype D; 25.0% (24/96) genotype A). HepG2 cells were transfected by wild-type or mutated linear HBV genome to assess pre-genomic RNA (pgRNA) and core-associated HBV-DNA levels, HBx-binding onto cccDNA by chromatin immunoprecipitation-based quantitative assay, and rate of apoptosis and cell-cycle progression by cytofluorimetry. RESULTS F30V was the only HBx mutation correlated with HCC (18.5% (5/27) in HCC patients versus 1.0% (1/96) in non-HCC patients, p 0.002); a result confirmed by multivariate analysis. In vitro, F30V determined a 40% and 60% reduction in pgRNA and core-associated HBV-DNA compared with wild-type (p <0.05), in parallel with a significant decrease of HBx binding to cccDNA and decreased HBx stability. F30V also decreased the percentage of apoptotic cells compared with wild-type (14.8 ± 6.8% versus 19.1 ± 10.1%, p <0.01, without affecting cell-cycle progression) and increased the probability of HBx-Ser-31 being phosphorylated by PI3K-Akt kinase (known to promote anti-apoptotic activity). CONCLUSIONS F30V was closely correlated with HBV-induced HCC in vivo, reduced HBV replicative efficiency by affecting HBx-binding to cccDNA and increased anti-apoptotic HBx activity in vitro. This suggests that F30V (although hampering HBV's replicative capacity) may promote hepatocyte survival, so potentially allowing persistent production of viral progeny and initiating HBV-driven hepatocarcinogenesis. Investigation of viral genetic markers associated with HCC is crucial to identify those patients at higher risk of HCC, who hence deserve intensive liver monitoring and/or early anti-HBV therapy.
Collapse
Affiliation(s)
- R Salpini
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | - M Surdo
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | - M F Cortese
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy; Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - G A Palumbo
- Department of Internal Medicine-DMISM, Sapienza University, Rome, Italy
| | - L Carioti
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | | | - A Spanò
- 'S. Pertini Hospital', Rome, Italy
| | | | - H Fleury
- Hôpital Pellegrin Tripode, Bordeaux, France
| | | | | | - C Mirabelli
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy; University of Michigan Medical School, Ann Arbor, MI, USA
| | - R Scutari
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | - A Sacco
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | - M Alkhatib
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy
| | | | - S Francioso
- Hepatology Unit, Tor Vergata University Hospital, Rome, Italy
| | - L Sarmati
- Infectious Diseases Unit, Tor Vergata University Hospital, Rome, Italy
| | - M Andreoni
- Infectious Diseases Unit, Tor Vergata University Hospital, Rome, Italy
| | - M Angelico
- Hepatology Unit, Tor Vergata University Hospital, Rome, Italy
| | | | - M Levrero
- Department of Internal Medicine-DMISM, Sapienza University, Rome, Italy; INSERM U1052 - Cancer Research Centre of Lyon, 69008 Lyon, France
| | - C F Perno
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy; Haematology and Oncohaematology, University of Milan, Italy
| | - L Belloni
- Department of Internal Medicine-DMISM, Sapienza University, Rome, Italy; Centre for Life NanoSciences, IIT-Sapienza, Rome, Italy
| | - V Svicher
- Department of Experimental Medicine and Surgery, University of Rome 'Tor Vergata' Rome, Italy.
| |
Collapse
|
5
|
Zhang Y, Wang S, Wen X, Zhang S, Yang Y. Association of ACYP2 and MPHOSPH6 genetic polymorphisms with the risk of hepatocellular carcinoma in chronic hepatitis B virus carriers. Oncotarget 2017; 8:86011-86019. [PMID: 29156773 PMCID: PMC5689663 DOI: 10.18632/oncotarget.20846] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 08/02/2017] [Indexed: 12/02/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is the dominant histologic type of primary liver cancer, and hepatitis B virus (HBV) infection is one of the major causes of HCC in the chronic HBV. Our study was investigated the association between the polymorphisms of ACYP2 and MPHOSPH6 genes and the risk of HCC induced by HBV infection. A total of 490 subjects were divided into two groups: 248 HBV patients with HCC (Case group), and 242 HBV patients without HCC (Control group). Unconditional logistic regression analysis was used to evaluate the association. The genetic association analysis revealed variant of rs12621038 in ACYP2 gene had a significant association with increasing the risk of HBV-induced HCC based on the genotype, dominant and additive model (P<0.05). Moreover, our results also showed that minor allele “C” of rs3751862 was prevalent in cases than controls (P<0.05), and rs3751862 significantly increased the risk of HCC in chronic HBV carriers under genotype and dominant model (P<0.05). In addition, the haplotype “T-G-G” in MPHOSPH6 showed a harmful factor for the HBV-induced HCC (P<0.05). The results suggested that ACYP2 and MPHOSPH6 as the plausible candidate genes may predict the risk of HCC after chronic HBV infection in Chinese Han population, and further investigations in studies with a larger sample size and other races are needed to validate our findings. These data provide a theoretical foundation for future studies of this correlation between the polymorphisms of ACYP2 and MPHOSPH6 genes and the HCC in chronic HBV carriers.
Collapse
Affiliation(s)
- Yingai Zhang
- Central Laboratory, Haikou People's Hospital, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan, China
| | - Shunlan Wang
- Central Laboratory, Haikou People's Hospital, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan, China
| | - Xiaohong Wen
- Central Laboratory, Haikou People's Hospital, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan, China
| | - Shufang Zhang
- Central Laboratory, Haikou People's Hospital, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan, China
| | - Yijun Yang
- Department of Hepatobiliary Surgery, Haikou People's Hospital, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan, China
| |
Collapse
|
6
|
Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, Svicher V. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget 2017; 8:15704-15715. [PMID: 28152517 PMCID: PMC5362517 DOI: 10.18632/oncotarget.14944] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Accepted: 12/27/2016] [Indexed: 02/07/2023] Open
Abstract
Background An impaired HBsAg-secretion can increase HBV oncogenic-properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. Methods This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. Results Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P <0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P <0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P <0.001). Conclusions Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.
Collapse
Affiliation(s)
- Romina Salpini
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Matteo Surdo
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Nadia Warner
- Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
| | - Maria Francesca Cortese
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Danny Colledge
- Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
| | - Sally Soppe
- Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
| | | | - Daniele Armenia
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Luca Carioti
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Fabio Continenza
- Laboratory of Monitoring Antiviral Drugs, National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani" Rome, Italy
| | - Domenico Di Carlo
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Patrizia Saccomandi
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Carmen Mirabelli
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy.,Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France
| | - Michela Pollicita
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Roberta Longo
- Unit of Microbiology, "S. Pertini Hospital", Rome, Italy
| | - Sara Romano
- Unit of Microbiology, "S. Pertini Hospital", Rome, Italy
| | | | - Alberto Spanò
- Unit of Microbiology, "S. Pertini Hospital", Rome, Italy
| | - Pascale Trimoulet
- Laboratoire de Microbiologie Fondamentale et Pathogénicité, Hôpital Pellegrin Tripode, Bordeaux, France
| | - Herve Fleury
- Laboratoire de Microbiologie Fondamentale et Pathogénicité, Hôpital Pellegrin Tripode, Bordeaux, France
| | - Jacopo Vecchiet
- Department of Medicine and Aging Sciences, "SS Annunziata" Hospital, Chieti, Italy
| | - Nerio Iapadre
- Infectious Diseases Unit, "S Salvatore" Hospital, L'Aquila, Italy
| | | | - Ada Bertoli
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Terenzio Mari
- Hepatology Unit, "Regina Margherita" Hospital, Rome, Italy
| | | | | | - Cesare Sarrecchia
- Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy
| | - Elisa Orecchini
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata" Rome, Italy
| | - Alessandro Michienzi
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata" Rome, Italy
| | - Massimo Andreoni
- Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy
| | | | - Mario Angelico
- Tor Vergata University Hospital, Hepatology Unit, Rome, Italy
| | - Jens Verheyen
- Tor Vergata University Hospital, Hepatology Unit, Rome, Italy
| | | | - Stephen Locarnini
- Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
| | - Carlo Federico Perno
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| | - Valentina Svicher
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata" Rome, Italy
| |
Collapse
|
7
|
Ochi Y, Hashimoto S, Kawabe N, Murao M, Nakano T, Kan T, Nakaoka K, Ohki M, Kurashita T, Takamura T, Nomura S, Nishikawa T, Fukui A, Osakabe K, Ichino N, Yoshioka K. HLA-DQ gene polymorphisms are associated with hepatocellular carcinoma and hepatitis B surface antigen in chronic hepatitis B virus infection. Hepatol Res 2017; 47:755-766. [PMID: 27580643 DOI: 10.1111/hepr.12812] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Revised: 08/14/2016] [Accepted: 08/29/2016] [Indexed: 01/31/2023]
Abstract
AIM Genome-wide association studies have revealed that single nucleotide polymorphism (SNP) of human leukocyte antigen (HLA)-DQ is associated with the clearance of hepatitis B surface antigen (HBsAg) in acute hepatitis B virus (HBV) infection. We examined the effects of SNPs on the development of hepatocellular carcinoma (HCC) and markers of HBV in chronic HBV infection. METHODS The SNPs of HLA-DQ (rs2856718 and rs7453920) were determined in 299 patients with chronic HBV infection. RESULTS In 224 hepatitis B e antigen (HBeAg)-negative patients, those with rs2856718 genotype AG + GG had significantly lower hepatitis B core-related antigen levels (P = 0.0184), less frequent treatment with nucleotide/nucleoside analogs (NAs) (P = 0.0433), and less frequent HCC development (P = 0.0256) than those with genotype AA. Multivariate analysis selected age (P = 0.0460), platelet count (P = 0.0481), γ-glutamyl transpeptidase (P = 0.0030), and nucleotide/nucleoside analog treatment (P = 0.0003) as factors independently associated with HCC development. HBeAg-negative patients with rs7453920 genotype GG had significantly lower HBsAg levels (P < 0.0001), a higher prevalence of HBV genotype C (P = 0.0063), and a lower prevalence of the wild-type basal core promoter region (P = 0.0045) than those with genotype AA + AG. Multivariate analysis selected age (P < 0.0001), platelet count (P = 0.0021), HBV DNA levels (P = 0.0314), wild type of precore region (P = 0.0015), and rs7453920 (P < 0.0001) as factors independently associated with HBsAg levels. CONCLUSION This study revealed an association between rs2856718 and HCC development and an association between rs7453920 and HBsAg levels.
Collapse
Affiliation(s)
- Yuka Ochi
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Senju Hashimoto
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Naoto Kawabe
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Michihito Murao
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Takuji Nakano
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Toshiki Kan
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Kazunori Nakaoka
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Masashi Ohki
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Takamitsu Kurashita
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Tomoki Takamura
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Sayuri Nomura
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Toru Nishikawa
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| | - Aiko Fukui
- Department of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan
| | - Keisuke Osakabe
- Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Toyoake, Japan
| | - Naohiro Ichino
- Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Toyoake, Japan
| | - Kentaro Yoshioka
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan
| |
Collapse
|
8
|
Lu G, Villa JA, Donlin MJ, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Antiviral Res 2016; 135:24-30. [PMID: 27693161 DOI: 10.1016/j.antiviral.2016.09.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 09/12/2016] [Accepted: 09/19/2016] [Indexed: 02/07/2023]
Abstract
Hepatitis B virus (HBV) causes hepatitis, cirrhosis, liver failure, and liver cancer, but the current therapies that employ either nucelos(t)ide analogs or (pegylated)interferon α do not clear the infection in the large majority of patients. Inhibitors of the HBV ribonuclease H (RNaseH) that are being developed with the goal of producing anti-HBV drugs are promising candidates for use in combination with the nucleos(t)ide analogs to improve therapeutic efficacy. HBV is genetically very diverse, with at least 8 genotypes that differ by ≥8% at the sequence level. This diversity is reflected in the viral RNaseH enzyme, raising the possibility that divergent HBV genotypes or isolates may have varying sensitivity to RNaseH inhibitors. To evaluate this possibility, we expressed and purified 18 patient-derived RNaseHs from genotypes B, C, and D. Basal RNaseH activity and sensitivity to three novel RNaseH inhibitors from three different chemotypes were assessed. We also evaluated four consensus HBV RNaseHs to determine if such sequences would be suitable for use in antiviral drug screening. The patient-derived enzymes varied by over 10-fold in their basal RNaseH activities, but they were equivalently sensitive to each of the three inhibitors. Similarly, all four consensus HBV RNaseH enzymes were active and were equally sensitive to an RNaseH inhibitor. These data indicate that a wide range of RNaseH sequences would be suitable for use in antiviral drug screening, and that genotype- or isolate-specific genetic variations are unlikely to present a barrier during antiviral drug development against the HBV RNaseH.
Collapse
Affiliation(s)
- Gaofeng Lu
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA; Department of Gastroenterology, The Second Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China
| | - Juan Antonio Villa
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - Maureen J Donlin
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - Tiffany C Edwards
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - Xiaohong Cheng
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - Richard F Heier
- Center for World Health and Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - Marvin J Meyers
- Center for World Health and Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA
| | - John E Tavis
- Department of Molecular Microbiology and Immunology and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO, USA.
| |
Collapse
|
9
|
Kim H, Lee SA, Kim BJ. X region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol 2016; 22:5467-5478. [PMID: 27350725 PMCID: PMC4917607 DOI: 10.3748/wjg.v22.i24.5467] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 05/17/2016] [Accepted: 06/02/2016] [Indexed: 02/06/2023] Open
Abstract
Chronic hepatitis B virus (HBV) infection remains a major health problem, with more than 240 million people chronically infected worldwide and potentially 650000 deaths per year due to advanced liver diseases including liver cirrhosis and hepatocellular carcinoma (HCC). HBV-X protein (HBx) contributes to the biology and pathogenesis of HBV via stimulating virus replication or altering host gene expression related to HCC. The HBV X region contains only 465 bp encoding the 16.5 kDa HBx protein, which also contains several critical cis-elements such as enhancer II, the core promoter and the microRNA-binding region. Thus, mutations in this region may affect not only the HBx open reading frame but also the overlapped cis-elements. Recently, several types of HBx mutations significantly associated with clinical severity have been described, although the functional mechanism in most of these cases remains unsolved. This review article will mainly focus on the HBx mutations proven to be significantly related to clinical severity via epidemiological studies.
Collapse
|
10
|
Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget 2016; 7:12525-36. [PMID: 26848866 PMCID: PMC4914302 DOI: 10.18632/oncotarget.7123] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 01/23/2016] [Indexed: 02/05/2023] Open
Abstract
Basal core promoter (BCP) A1762T/G1764A dual mutations in hepatocarcinogenesis remain controversial. Published studies up to June 1, 2015 investigating the frequency of A1762T/G1764A dual mutations from chronic hepatitis B virus (HBV) infection, including hepatocellular carcinoma (HCC), were systematically identified. A total of 10,240 patients with chronic HBV infection, including 3729 HCC cases, were included in 52 identified studies. HCC patients had a higher frequency of BCP A1762T/G1764A dual mutations compared with asymptomatic HBsAg carriers (ASC) and patients with chronic hepatitis B (CHB) and liver cirrhosis (LC) (OR = 5.59, P < 0.00001; OR = 2.87, P < 0.00001; OR = 1.55, P = 0.02, respectively). No statistically significant difference was observed in the frequency of A1762T/G1764A dual mutations in cirrhotic HCC versus non-cirrhotic HCC patients (OR = 2.06, P = 0.05). Chronic HBV-infected patients and HCC patients with genotype B had a significantly lower risk of A1762T/G1764A dual mutations compared with patients with genotype C (OR = 0.30, P < 0.0001 and OR = 0.34, P = 0.04, respectively). In HBV genotype C subjects, A1762T/G1764A dual mutations contributed to significantly higher risk for HCC developing compared with non-mutation ones (OR = 3.47, P < 0.00001). In conclusion, A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma, particularly in an HBV genotype C population, even without progression to cirrhosis.
Collapse
Affiliation(s)
- Zongguo Yang
- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| | - Liping Zhuang
- 2 Fudan University Shanghai Cancer Center, Shanghai, China
- 3 Shanghai Medical College, Fudan University, Shanghai, China
| | - Yunfei Lu
- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| | - Qingnian Xu
- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| | - Bozong Tang
- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| | - Xiaorong Chen
- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| |
Collapse
|
11
|
ARTARINI ANITA, GEBY JESSICA HANARY, RINI KARTIKASARI RADEN, RIANI CATUR, SOEFIE RETNONINGRUM DEBBIE. Detection of Hepatitis B Virus X Gene Mutation from Local Clinical Samples. MICROBIOLOGY INDONESIA 2016. [DOI: 10.5454/mi.10.1.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
12
|
Niller HH, Ay E, Banati F, Demcsák A, Takacs M, Minarovits J. Wild type HBx and truncated HBx: Pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms. Rev Med Virol 2015; 26:57-73. [PMID: 26593760 DOI: 10.1002/rmv.1864] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 09/30/2015] [Accepted: 10/15/2015] [Indexed: 12/23/2022]
Abstract
Hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma. The molecular mechanisms of tumorigenesis are complex. One of the host factors involved is apparently the long-lasting inflammatory reaction which accompanies chronic HBV infection. Although HBV lacks a typical viral oncogene, the HBx gene encoding a pleiotropic regulatory protein emerged as a major player in liver carcinogenesis. Here we review the tumorigenic functions of HBx with an emphasis on wild type and truncated HBx variants, and their role in the transcriptional dysregulation and epigenetic reprogramming of the host cell genome. We suggest that HBx acquired by the HBV genome during evolution acts like a cellular proto-onc gene that is activated by deletion during hepatocarcinogenesis. The resulting viral oncogene (v-onc gene) codes for a truncated HBx protein that facilitates tumor progression. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Hans Helmut Niller
- Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Eva Ay
- Department of Retrovirology, National Center for Epidemiology, Budapest, Hungary
| | - Ferenc Banati
- RT-Europe Nonprofit Research Center, Mosonmagyarovar, Hungary
| | - Anett Demcsák
- University of Szeged, Faculty of Dentistry, Department of Oral Biology and Experimental Dental Research, Szeged, Hungary
| | - Maria Takacs
- Division of Virology, National Center for Epidemiology, Budapest, Hungary
| | - Janos Minarovits
- University of Szeged, Faculty of Dentistry, Department of Oral Biology and Experimental Dental Research, Szeged, Hungary
| |
Collapse
|